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Background: Endometrial carcinoma is one of the most common gynecologic malignancies. Estrogen plays a
critical role in its pathogenesis, but the underlying mechanism is not clear. Nucleophosmin 1 (NPM1), a
multifunctional protein involved in many cellular activities, has been implicated in the tumorigenesis processes.
However, the role of NPM1 in endometrial carcinogenesis remains to be elucidated. The present study was aimed
to elucidate the role of NPM1 in different clinical stages of human endometrial carcinoma and the underlying
mechanism of NPM1 action.
Methods: The distribution and expression of NPM1 in normal endometrium, FIGO stages I to IV endometrial carcinoma
tissues was analyzed using immunohistochemistry, RT-qPCR and Western blotting. The association between NPM1
expression and estrogen and estrogen receptor signaling was investigated in primary-cultured FIGO stage I endometrial
adenocarcinoma cells.
Results: A strong positive correlation between NPM1 level and the clinical stage and histological grade of endometrial
carcinomas was observed. Expression of NPM1 was up-regulated by estrogen in primary-cultured human endometrial
adenocarcinoma cells. Furthermore, estrogen increased NPM1 level via estrogen receptor-α (ERα) signaling, nor
estrogen receptor-β signaling.
Conclusions: Expression of NPM1 was gradually increased with the increase of clinical stages of endometrial
carcinomas. Overexpression of NPM1 may play a role in the effects of estrogen on the malignant progression of
endometrioid adenocarcinoma via ERα signaling. These findings may extend our understanding of the oncogenesis
of steroid hormone-related cancers and have significance for the diagnosis and treatment of this carcinoma.
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Endometrial carcinomas is one of the three common
female genital tract malignancy, ranking fourth among
invasive tumors in women worldwide with 287000 new
patients and estimated 74000 deaths per year [1]. In recent
years, the incidence of endometrial cancer increased year
by year. In China, the morbidity of endometrial cancer
increases constantly in population, and the age of onset
are younger and younger [2,3]. Based on characteristic
epidemiology, clinical symptoms and lesions, two different* Correspondence: yanliwangyl@163.com
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lated to estrogen stimulation and type II unrelated to
estrogen stimulation [4]. Over 80% of endometrial carcin-
omas are type I, also known as endometrioid adenocarcin-
omas [4]. So far, there has been much research on the
molecular events estrogen involved that contribute to the
development and progression of this disease. But fur-
ther work is still needed to elaborate the potential
mechanism of estrogen action.
Nucleophosmin (NPM, also known as B23 [5], numatrin
[6] or NO38 [7]), is a nucleolar phosphoprotein found
at high levels in the granular regions of the nucleolus
[8,9], and it may shuttle in and out of the nucleolus,
and between nucleus and cytoplasm [10]. NPM1 is thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has proved to be a multifunctional protein that is involved
in various cellular activities, including transport of pre-
ribosomal particles and ribosome biogenesis [11], centro-
some duplication [12,13], response to stress-stimuli [14,15],
regulation of DNA transcription, maintenance of genomic
stability and embryonic development [16], which suggests a
role for NPM1 in tumorigenesis. Dysregulation of NPM1
has been found in many solid and hematological malignan-
cies. NPM1 is mutated or aberrantly localized in about
one-third of patients with acute myeloid leukaemia (AML)
[17]. In addition, NPM1 is reported to be overexpressed in
solid tumors of diverse histological origins, including
astrocytomas [18], as well as colon [19], hepatocellular
[20], bladder [21], breast [22], ovarian [23] and prostate
[24] carcinomas. The alteration of NPM1 in human cancer
(through overexpression or genetic modification) indicates
that NPM1 might play a role as both an oncogene and
a tumor suppressor, depending on its dosage and level
of expression [25].
However, the role of NPM1 in endometrial carcinomas
is still not well-known. Recent research has found NPM1’s
expression is associated with the presence of estrogen
receptor-α (ERα) in Ishikawa and ARK1 endometrial
cancer cells [26]. Moreover, studies in human breast
cancer also indicate a hormonal contribution to NPM1
expression and localization [27]. However, no studies
which related to human endometrial carcinoma clinical
stages were reported. In the present study, we investigated
NPM1 alteration in different clinical stages of endometrial
carcinoma and analyzed the estrogen regulation of NPM1
expression in primary-cultured International Federation of
Gynecology and Obstetrics (FIGO) stage I human endo-
metrial adenocarcinoma cells.
Results
Expression of NPM1 was increased with the increase of
clinical stages of endometrial carcinomas
To determine the distribution of NPM1 in different clin-
ical stages of endometrial carcinoma, NPM1 expression
level was investigated in 31 endometrial tissues, including
normal endometrium (n = 4), FIGO stage I (n = 8), FIGO
stage II (n = 6), FIGO stage III (n = 9) and FIGO stage IV
(n = 4) endometrial carcinoma tissues, using IHC, qRT-
PCR and Western blotting. NPM1 proteins were stained
in the nuclei of glandular cells (Figure 1). Immunostaining
intensity of NMP1 gradually increased with the deterior-
ation of endometrial carcinoma (Figure 1), indicating that
NMP1 expression is up-regulated in endometrial car-
cinogenesis and metastasis. Similarly, the NMP1 mRNA
level detected by qRT-PCR and the NMP1 protein level
detected by Western blotting were also gradually in-
creased with the deterioration of endometrial carcinoma
(P < 0.05, Figure 2).Expression of NPM1 was up-regulated by estrogen in
primary-cultured human endometrial adenocarcinoma cells
To investigate if there is a possible hormonal regulation of
NPM1 expression, we quantified NPM1 expression levels
in primary-cultured FIGO stages I endometrial adenocar-
cinoma cells stimulated with estrogen (E2 0, 0.1, 0.5, 1,
5 μm/ml) for 24 h using qRT-PCR and Western blotting.
As shown in Figure 3, the NPM1 mRNA level of the
primary-cultured cells was significantly increased after
treatment with E2 in a dose-dependent manner, and this
result was similar to the protein level detected by Western
blotting.
Expression of NPM1 was regulated through estrogen
receptor-α signaling
A previous study demonstrated that E2 increased NPM1
protein expression in an ERα-dependent manner in
Ishikawa and ARK1 human endometrial cancer cell lines
[26]. And the ERα expression as a result of E2 treatment
in primary-cultured FIGO stages I endometrial adenocar-
cinoma cells exhibited a similar tendency to that of NPM1
(Figure 4). So we investigated whether the estrogen-
regulated NPM1 expression was correlated with estrogen
receptor-α in the primary-cultured FIGO stages I human
endometrial adenocarcinoma cells. As shown in Figure 5,
addition of estrogen receptor-α antagonist ICI 182780
attenuated E2-induced mRNA and protein expression of
NPM1 in the primary-cultured FIGO stages I endometrial
adenocarcinoma cells. In contrast, NPM1 mRNA and pro-
tein expression was enhanced upon the stimulation of
ERα-specific agonist PPT, while ERβ-specific agonist DPN
had no significant effect. ICI 182780 also attenuated the
NPM1 mRNA and protein expression increase induced
by PPT.
Discussion
NMP1 has been identified as a molecule involved in
development and progress of many human cancers [25].
The NPM1 protein is frequently overexpressed in solid
tumours of diverse histological origin, and it has been
regarded as a marker for gastric [28], colon [19], ovarian
[23] and prostate [24] carcinomas. However, its effect on
endometrial carcinoma has not been well-studied. In this
study, NPM1 immunostaining frequency and expression
level was found to be linked to the clinical stage of
endometrial carcinoma, and in vitro studies using FIGO
stages I human endometrial adenocarcinoma cells in pri-
mary culture demonstrated that ERα-mediated signaling
regulated expression of NPM1.
The results of haematoxylin-eosin staining, as shown in
Figure 1, revealed significant changes of cellular morph-
ology during the endometrial carcinoma progression.
With the development of tumors, the stromal cells initi-
ated malignancy change of cells at first. Then endometrial
Figure 1 (See legend on next page.)
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Figure 1 Immunolocalization of NPM1 in normal endometrium, FIGO stages I to IV endometrial carcinoma tissues. HE, Morphology of
normal endometrium (A) and different stages endometrioid cancer tissues (B, C, D, E) stained by haematoxylin-eosin. NPM1, NPM1 staining was
immunodetected in the glandular cells of all samples. The immunoreactivity of NPM1 was gradually increased from normal endometrium (F), FIGO stages
I to IV endometrial carcinoma (G, H, I, J). NE: normal endometrium; I: FIGO stage I endometrial carcinoma; II: FIGO stage II endometrial carcinoma; III: FIGO
stage III endometrial carcinoma; IV: FIGO stage IV endometrial carcinoma; UG: uterine gland; GEp: glandular epithelium; Scale bars = 50 μm.
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organized structure of endometrial tissues was more and
more difficult to be distinguished.
Overexpression of NPM1 has been reported in many
types of major human solid tumors including colon, liver,
stomach, ovary, bladder, breast and prostate carcinomas
[25]. And expression of NPM1 is higher in many types of
tumor and proliferating cells than in normal resting cells
[29,30]. Our study using clinical samples showed that
NPM1 is significantly more abundant in endometrial
carcinoma tissues than in normal endometrial tissues.
And furthermore the level of NPM1 is strongly linked to
the initiation and progression of endometrial carcinoma.
These findings suggested that the overexpression of
NPM1 may play an important role in carcinogenesis and
development of endometrial carcinoma. And NPM1 mayFigure 2 The relative mRNA level (A) and the protein level (B) of NMP
development of endometrial carcinoma. Control: normal endometrium;
carcinoma; III: FIGO stage III endometrial carcinoma; IV: FIGO stage IV endo
**P < 0.01, *** P < 0.001 indicate significant differences from the control grobe used as a new biomarker for judging the progression
and prognosis of endometrial carcinoma. The correlation
between NPM1 and the stage of tumor progression aslo
have been observed in some patients. For example, over-
expression of NPM1 mRNA was independently associated
with bladder cancer recurrence and progression to more
advanced disease stages [21].
Prolonged estrogenic stimulation of the endometrium is
believed to occur in carcinomas developing not only in
the young but also postmenopausal women [31]. Further-
more, it’s also shown that women with endometrial cancer
present higher oestrone and oestradiol concentrations
compared with healthy women [32-35]. However, the
pathogenesis of this disease is less completely understood
and the role of estrogens in the initiation and progression
of this disease still requires further consideration. It is well1 were both gradually increased during the carcinogenesis and
I: FIGO stage I endometrial carcinoma; II: FIGO stage II endometrial
metrial carcinoma; β-tubulin was used as a loading control. *P < 0.05,
up.
Figure 3 E2 increased NPM1 mRNA expression (A) and protein expression (B) of primary-cultured FIGO stages I endometrial adenocarcinoma
cells in a dose-dependent manner. E2, 17β-estradiol. *P < 0.05, **P < 0.01, *** P < 0.001 indicate significant differences from those treated with 0 μm/ml E2.
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frequently altered in human cancers and aberrantly
expressed NPM contributes to tumorigenesis [25,36].
NPM overexpression leads to increased cell growth and
proliferation and inhibition of differentiation and apop-
tosis [25,36]. Here we showed that expression of NPM1
in primary human endometrial adenocarcinoma cells
was up-regulated by estrogen in a dose-dependent
manner and estrogen increased NPM1 expression via
ERα-mediated signaling not ERβ, which are consistent
with others’ study with endometrial cancer cell lines
Ishikawa and ARK1 [26]. NPM1 was also required for
the E2-induced proliferation of endometrial cancer cells
[26]. These results suggested a role of NPM1 in the
effects of estrogen on the genesis, progress and progno-
sis of endometrial carcinoma, which may provide new
insights into the molecular mechanism of estrogen in
endometrial carcinoma.
Conclusions
Expression of NPM1 was gradually increased with the
increase of clinical stages of endometrial carcinomas.
Overexpression of NPM1 may play a role via ERα in theeffects of estrogen on the malignant progression of
endometrioid adenocarcinoma, which may extend our
understanding of the oncogenesis of steroid hormone-




Normal endometrial tissues were collected from patients
(n = 21; mean patient age = 52.2 ± 13.31) undergoing hys-
terectomies for benign gynecological diseases. Endometrial
samples from adenocarcinoma (endometrioid and serous
types) were obtained from patients (n = 56; mean patient
age = 59.4 ± 19.8) undergoing hysterectomy at the Depart-
ment of gynecology, The First Affiliated Hospital, College
of Medicine, Zhejiang University. None had received
pre-operative chemotherapy, radiotherapy or endocrine
therapy. Patients were evaluated in accordance with the
(FIGO) criteria 2009. The number of patients classified
as FIGO stage I, II, III and IV were 37, 6, 9 and 4, respect-
ively. This project was approved by the Medical Ethics
Review Board of the First Affiliated Hospital, College of
Medicine, Zhejiang University, in accordance with the
Figure 4 E2 increased ERα mRNA expression (A) and protein expression (B) of primary-cultured FIGO stages I endometrial adenocarcinoma
cells in a dose-dependent manner. This tendency was similar to that of NPM1 (Figure 3). E2, 17β-estradiol. *P < 0.05, **P < 0.01, *** P < 0.001 indicate
significant differences from those treated with 0 μm/ml E2.
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informed consent was obtained from each participant/
guardian.
Chemicals
17β-estradiol (E2) and DMSO were purchased from
Sigma-Aldrich (St. Louis, MO, USA). ICI 182 780,
4′,4″,4‴-(4-propyl-[1H]-pyrazole-1,3,5-triyl)tris-phenol
(PPT) and 2,3-bis-(4–ydroxyphenyl)-propionitrile (DPN)
were purchased from Tocris Cookson Ltd (Bristol, UK).
Primary culture of human endometrial epithelial cells
The endometrial epithelial cells was derived from stage I
endometrial adenocarcinoma and normal endometrium.
The primary culture of human endometrial epithelial
cells procedures were performed as previously reported
[37,38]. After hysterectomy and under aseptic condi-
tions, about 2–4 cm3 of cancerous tissue was immedi-
ately removed from the endometrium and placed in
separate transport tubes containing Dulbecco’s Modified
Eagle Medium: Nutrient Mixture F-12 (DMEM/F12)
culture medium (Gibco, USA) with penicillin (100 U/ml)
and streptomycin (100 mm/ml) for transport to the la-
boratory on wet ice. The tissues were trimmed ofnecrosis and washed three in sterile phosphate buffered
saline (PBS). Rinsed tissues were diced to 1 mm3 pieces,
then digested in calcium and magnesium free Hank’s
Balanced Salt Solution (HBSS) (Invitrogen, USA) with
2.5 mg/ml collagenase type IV-S (Gibco, USA) at 37°C
for up to 1.5 h with gentle agitation. Cells were washed
three with 50 ml sterile HBSS and pelleted by centrifu-
gation at 800 rpm at 4°C for 5 min. Washed cells were
filtered through a 38 μm autoclaved stainless steel
micropore sieves (Newark Wire Cloth Co., USA) to iso-
late stromal cells and the remaining clumps (containing
epithelial cells) washed in HBSS. The clumps were sub-
jected to a second digestion for 30 min before being
filtered through 250 μm sieves and 38 μm sieves,
respectively. Cells were recovered by inverting and wash-
ing the 38 μm sieves and incubated in HBSS with 0.05%
trypsin (Gibco, USA), 0.02%EDTA (Sigma, USA) and
0.05 mg/ml DNAase I (Sigma, USA) for 8 min at 37°C.
The solution was centrifuged at 1000 rpm at 4°C for
5 min, and washed three in HBSS. Then the cells were
resuspended in DMEM/F12 with 10% FBS (Invitrogen,
USA), 2 mM L-glutamine (Invitrogen, USA), 100 U/ml
penicillin and 100 mm/ml streptomycin and plated in
25 cm2 flasks after being assessed for cell viability using
Figure 5 Expression of NPM1 was regulated via the estrogen receptor-α (ERα) signaling in the primary-cultured FIGO stages I
endometrial adenocarcinoma cells. The NMP1 mRNA expression (A) and protein expression (B) in primary-cultured cells treated with DMSO,
1 μM E2, 100 nM ICI, 1 μM E2 and 100 nM ICI, 1 μM PPT, 1 μM PPT and 100 nM ICI, 1 μM DPN for 24 h, respectively, were detected by qRT-PCR and
Western blotting. E2, 17β-estradiol; ICI, ICI 182 780; PPT, 4,4′,4″(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol; DPN, 2,3-bis-(4-ydroxyphenyl)–propionitrile.
*P < 0.05, **P < 0.01 indicate significant differences from those treated with DMSO.
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cell cultures were washed twice with PBS, and fresh
medium was added. Cells were then passaged using tryp-
sin once the monolayer reached 80–90% confluence and
used to seed in new 25 cm2 flasks or undergo processing
for RNA and protein isolation. By the third passage, few
fibroblast and stromal cells were observed. 24 h prior to
estradiol treatment, cells were washed in PBS and then
grown in steroid-depleted medium lacking phenol red
(Invitrogen/Life Technologies, Carlsbad, CA, USA).
Immunohistochemistry
Representative blocks of formalin-fixed, paraffin-embedded
endometrial tissues were cut at 4 μm thick, placed on slides
coated with poly-L-lysine, deparaffinized in xylene and
rehydrated with a graded series of ethanol. All samples were
stained with hematoxylin and eosin for histopathologic
examination to select the representative regions. Then after
antigen retrieval, quenching endogenous peroxidase and
blocking the nonspecific binding, sections were incubatedin the mouse anti-human NPM1 antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), at a dilution of 1:50,
overnight at 4°C. In negative control sections, the primary
antibody was replaced with non-immune mouse serum.
After washing, the sections were incubated in correspond-
ing secondary antibodies for 2 h at room temperature,
followed by incubation with the Strept-Avidin Biotin com-
plex (Dakopatts, Glostrup, Denmark). Peroxidase activity
was visualized in chromogen 3,3′-diaminobenzidine solu-
tion(Dakopatts, Glostrup, Denmark). After being coun-
terstained lightly with hematoxylin, the sections were
dehydrated through an ethanol series to xylene, mounted,
examined and photographed. A brown precipitate was
considered as positive result.
Western blotting
Total protein was isolated from the tissue samples or
primary-cultured cells using the Tissue or Cell Total
Protein Extraction Kit (Sangon, Shanghai, China), respect-
ively, according to the manufacturer’s protocol. The protein
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Kit (Pierce, Rockford, IL, USA). After boiled for 5mins
at 100°C, about 30 μg Proteins were separated by 12%
SDS–PAGE, and then electro-transferred onto PVDF
membranes (0.45 μm, Millipore, Billerica, MA, USA). After
blocking with 5% nonfat milk, the membrane was then
incubated with the mouse anti-human NPM1 antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
the rabbit anti-ERα (MC-20) polyclonal antibody (1:1000;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), over-
night at 4°C, followed by incubation with horseradish
peroxidase-conjugated secondary antibody for 2 h at room
temperature. The immunoreactivity was then visualized
with an enhanced chemiluminescence reaction (Amersham
Pharmacia Biotech, Piscataway, NJ, USA) and autoradiog-
raphy. All the immunoblots were also probed with the
rabbit anti-β-tubulin polyclonal antibody (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) as a loading
control.
Quantitative real-time reverse transcription PCR
Total RNA was extracted from the tissue samples or
primary-cultured cells using Trizol reagent (Invitrogen,
San Diego, CA, USA), respectively, according to the
manufacturer’s instructions. 1 μg of total RNA was reverse
transcribed to single-strand cDNA using random exapri-
mers and 200 U MMLV reverse transcriptase (Invitrogen,
San Diego, CA, USA) according to the manufacturer’s
directions. Quantitative real-time polymerase chain reac-
tion (qPCR) analyses were performed in a 20 μl reaction
volume in triplicate using TransStar SYBR Green qPCR
Supermix (TransGen Biotech, Beijing, China), according
to the manufacturer’s recommended protocol, and data
were collected and analyzed by the ABI Prism 7900 HT
instrument (Applied Biosystems, Carlsbad, CA, USA).
The transcript levels were normalized to the glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) values of the
respective sample. Relative quantitative measure of genes
was evaluated using 2-ΔΔCt (where Ct is the threshold
cycle). The primers for NPM1, ERα and GAPDH were
synthesized by Shanghai Sangon Company, Shanghai,
China, which are as follows:
NPM1: forward, 5′-GGGGCTTTGAAATAACACCA-3′;
reverse, 5′-GAACCTTGCTACCACCTCCA-3′.






Data are shown as mean ± standard deviation (SD) for
each group. All experiments were performed in triplicateand averaged from >3 independent experiments. Statis-
tical analysis was carried out using SPSS 17.0 software
(SPSS, Inc., Chicago, IL, USA). Statistical comparisons
between groups were made using one-way analysis of
variance (ANOVA) followed by Student’s t-test. Value of
P < 0.05 was considered statistically significant.
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